Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.

Key Points: Question: Is neoadjuvant nivolumab with chemotherapy followed by response-adapted locoregional therapy effective and well tolerated in patients with human papillomavirus−positive oropharyngeal carcinoma (HPV+ OPC)? Findings: This phase 2 nonrandomized controlled trial of 73 patients with...

Descripción completa

Detalles Bibliográficos

Publicado en:	JAMA Oncology Vol. 10; no. 7; pp. 923 - 932
Autores principales:	Rosenberg, Ari J., Agrawal, Nishant, Juloori, Aditya, Cursio, John, Gooi, Zhen, Blair, Elizabeth, Chin, Jeffrey, Ginat, Daniel, Pasternak-Wise, Olga, Hasina, Rifat, Starus, Anna, Jones, Frederick S., Izumchenko, Evgeny, MacCracken, Ellen, Wolk, Rachelle, Cipriani, Nicole, Lingen, Mark W., Pearson, Alexander T., Seiwert, Tanguy Y., Haraf, Daniel J.
Formato:	research tables/charts Journal Article
Publicado:	American Medical Association Jul2024
Acceso en línea:	Ver este registro en EBSCOhost